Zimmer Biomet Q3 sales rise 9.7% to $2.001 billion; GAAP EPS falls to $1.16
Zimmer Biomet reported third-quarter 2025 net sales of $2.001 billion, up 9.7% from a year earlier, and adjusted diluted EPS of $1.90, up 9.2%. GAAP diluted EPS was $1.16, down from $1.23, as net earnings fell to $230.9 million from $249.1 million, so shareholders see higher sales but lower reported profit. The company kept its full-year reported revenue and adjusted EPS guidance unchanged and narrowed its constant currency and organic revenue ranges.
Key points
- Q3 net sales $2.001 billion, up 9.7% reported, 8.6% constant currency and 5.0% organic constant currency
- GAAP diluted EPS $1.16 vs $1.23 a year earlier; adjusted diluted EPS $1.90, up 9.2%
- Full-year 2025 adjusted diluted EPS guidance maintained at $8.10 to $8.30; reported revenue growth maintained at 6.7% to 7.7%
- Organic constant currency revenue growth guidance narrowed to 3.5% to 4.0% from 3.5% to 4.5%
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.